{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:41:59Z","timestamp":1779925319354,"version":"3.53.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Innovative Medicines Initiative Joint Undertaking","award":["115217 (DIRECT)"],"award-info":[{"award-number":["115217 (DIRECT)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00125-017-4519-5","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T10:49:02Z","timestamp":1513680542000},"page":"607-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Rates of glycaemic deterioration in a real-world population with type 2 diabetes"],"prefix":"10.1007","volume":"61","author":[{"given":"Louise A.","family":"Donnelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex S. F.","family":"Doney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Jennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan R.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"4519_CR1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M","volume":"15","author":"J Levy","year":"1998","unstructured":"Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR (1998) Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15:290\u2013296","journal-title":"Diabet Med"},{"key":"4519_CR2","doi-asserted-by":"crossref","unstructured":"U.K. Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249\u20131258","DOI":"10.2337\/diab.44.11.1249"},{"key":"4519_CR3","doi-asserted-by":"crossref","unstructured":"Turner R, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350: 1288\u20131293","DOI":"10.1016\/S0140-6736(97)03062-6"},{"key":"4519_CR4","doi-asserted-by":"crossref","unstructured":"Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (1998) UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15: 297\u2013303","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W"},{"key":"4519_CR5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diabet.2009.11.006","volume":"36","author":"A Ringborg","year":"2010","unstructured":"Ringborg A, Lindgren P, Yin DD, Martinell M, Stalhammar J (2010) Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. Diabetes Metab 36:198\u2013203","journal-title":"Diabetes Metab"},{"key":"4519_CR6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2337\/dc13-1995","volume":"37","author":"K Zhou","year":"2014","unstructured":"Zhou K, Donnelly LA, Morris AD et al (2014) Clinical and genetic determinants of progression of type 2 diabetes: a DIRECT study. Diabetes Care 37:718\u2013724","journal-title":"Diabetes Care"},{"key":"4519_CR7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2337\/diacare.28.5.995","volume":"28","author":"MN Cook","year":"2005","unstructured":"Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR (2005) Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28:995\u20131000","journal-title":"Diabetes Care"},{"key":"4519_CR8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2337\/dc07-1934","volume":"31","author":"LN Pani","year":"2008","unstructured":"Pani LN, Nathan DM, Grant RW (2008) Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care 31:386\u2013390","journal-title":"Diabetes Care"},{"key":"4519_CR9","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2337\/dc13-2738","volume":"37","author":"B Waldman","year":"2014","unstructured":"Waldman B, Jenkins AJ, Davis TM et al (2014) HDL-C and HDL-C\/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. Diabetes Care 37:2351\u20132358","journal-title":"Diabetes Care"},{"key":"4519_CR10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1464-5491.2002.00745.x","volume":"19","author":"TM Wallace","year":"2002","unstructured":"Wallace TM, Matthews DR (2002) Coefficient of failure: a methodology for examining longitudinal beta-cell function in type 2 diabetes. Diabet Med 19:465\u2013469","journal-title":"Diabet Med"},{"key":"4519_CR11","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427\u20132443","journal-title":"N Engl J Med"},{"key":"4519_CR12","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/01.ATV.0000147897.57527.e4","volume":"24","author":"AS Doney","year":"2004","unstructured":"Doney AS, Fischer B, Leese G, Morris AD, Palmer CN (2004) Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 24:2403\u20132407","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4519_CR13","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1161\/CIRCULATIONAHA.104.509224","volume":"111","author":"AS Doney","year":"2005","unstructured":"Doney AS, Lee S, Leese GP, Morris AD, Palmer CN (2005) Increased cardiovascular morbidity and mortality in type 2 diabetes is associated with the glutathione S transferase theta-null genotype: a Go-DARTS study. Circulation 111:2927\u20132934","journal-title":"Circulation"},{"key":"4519_CR14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc11-1465","volume":"35","author":"JA Hirst","year":"2012","unstructured":"Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ (2012) Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 35:446\u2013454","journal-title":"Diabetes Care"},{"key":"4519_CR15","doi-asserted-by":"crossref","first-page":"525093","DOI":"10.1155\/2012\/525093","volume":"2012","author":"G Dalmazi Di","year":"2012","unstructured":"Di Dalmazi G, Pagotto U, Pasquali R, Vicennati V (2012) Glucocorticoids and type 2 diabetes: from physiology to pathology. J Nutr Metab 2012:525093","journal-title":"J Nutr Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-017-4519-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4519-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4519-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T05:15:27Z","timestamp":1517980527000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-017-4519-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["4519"],"URL":"https:\/\/doi.org\/10.1007\/s00125-017-4519-5","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,19]]}}}